Oral anti-angiogenesis treatment plus chemotherapy is not more efficacious than bevacizumab plus chemotherapy in metastatic colorectal cancer.
D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D009362:Neoplasm Metastasis
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D000068258:Bevacizumab; C530716:nintedanib